Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE (EPA:OSE) commences pivotal Phase III trial for Tedopi
Published by Jyoti Prakash

OSE Immunotherapeutics has announced the initiation of the much-awaited Phase III registrational study for lead asset Tedopi, the most advanced therapeutic cancer vaccine currently in development. The pivotal study, termed Artemia, will be a randomised, open-label trial evaluating Tedopi as a second-line monotherapy for HLA-A2 positive patients with metastatic non-small cell lung cancer. We note that the study will focus on patients with secondary resistance to immune checkpoint inhibitors, a cohort that saw the maximum benefit in the preceding Atalante-1 trial. Top-line results are expected by 2027.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free